The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Non-Insulin Therapies For Diabetes Market During The Forecast Period 2026–2030?
The non-insulin therapies for diabetes market size has experienced significant growth in recent years. This market is projected to increase from $21.21 billion in 2025 to $22.59 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.5%. Historically, the expansion of this market can be attributed to the high prevalence of type 2 diabetes, the widespread reliance on oral hypoglycemic agents, challenges with patient adherence to insulin therapy, the growth in hospital and retail pharmacy distribution channels, and the introduction of multiple new drug classes.
The market for non-insulin therapies for diabetes is projected to experience strong growth in the next few years. It is anticipated to reach $28.39 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.9%. This expansion during the forecast period is attributed to factors such as the increasing adoption of non-insulin drug combinations, the rising use of GLP-1 and SGLT2 inhibitors, the widening of online pharmacy channels, the evolving personalized and precision medicine approaches, and the advancing integration of digital health and remote monitoring. Prominent trends for the forecast period include the increasing embrace of personalized diabetes management, the greater utilization of AI-driven glucose monitoring systems, the expanding integration of telemedicine-linked therapy solutions, the broader implementation of data-driven clinical decision support, and the progressive deployment of connected devices for remote patient care.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16494&type=smp
What Underlying Factors Are Accelerating The Growth Of The Non-Insulin Therapies For Diabetes Market?
The rising occurrence of diabetes is projected to drive the expansion of non-insulin therapies for the diabetes market in the future. Diabetes, a long-term medical ailment, is identified by elevated blood glucose (sugar) concentrations. This condition develops when the body either fails to produce adequate insulin or cannot effectively utilize the insulin it generates. The increase in diabetes cases stems from various factors, including inactive lifestyles, poor dietary habits, genetic susceptibility, an aging demographic, obesity, ethnic background, insufficient public knowledge, restricted healthcare access, and environmental influences. Non-insulin treatments for diabetes manage the condition by boosting insulin sensitivity, decreasing hepatic glucose production, augmenting glucose absorption in muscle cells, and improving comprehensive glycemic regulation. For example, data from March 2024, provided by the UK government agency Office for Health Improvement & Disparities, showed that the GP-registered prevalence of type 2 diabetes in adults aged 17 and above climbed to 7.0%, an increase from 6.8% in March 2023. Consequently, the growing prevalence of diabetes is fueling the expansion of non-insulin therapies for the diabetes market.
What Market Segments Are Evaluated Within The Non-Insulin Therapies For Diabetes Market?
The non-insulin therapies for diabetes market covered in this report is segmented –
1) By Type: Biguanides, Sulfonylureas, Thiazolidinediones (TZDs), DPP 4 Inhibitors, GLP 1 Analogs Or Agonists, SGLT2 Inhibitors
2) By Route Of Administration: Oral, Injectable
3) By Application: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals Or Clinics, Homecare Or Patients, Other End-Users
Subsegments:
1) By Biguanides: Metformin, Combination Of Metformin With Other Drugs
2) By Sulfonylureas: Glimepiride, Glipizide, Glyburide
3) By Thiazolidinediones (TZDs): Pioglitazone, Rosiglitazone
4) By DPP 4 Inhibitors: Sitagliptin, Saxagliptin, Linagliptin
5) By GLP 1 Analogs Or Agonists: Exenatide, Liraglutide, Dulaglutide
6) By SGLT2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin
How Are Trends Impacting The Non-Insulin Therapies For Diabetes Market?
Leading companies within the non-insulin therapies for diabetes market are concentrating on creating innovative solutions, including non-insulin GLP-1 receptor agonists, with the aim of broadening available treatments, enhancing glycemic management, and solidifying their market standing in the field of diabetes and obesity care. The launch of non-insulin GLP-1 receptor agonists signifies the introduction of new treatments that target GLP-1 receptors, facilitating the regulation of blood glucose and promoting weight loss, all without requiring insulin. An example of this is the launch of Mounjaro (tirzepatide) in India in March 2025 by Eli Lilly and Company, a US-based pharmaceutical firm focused on diabetes and metabolic treatments, after receiving clearance from the Central Drugs Standard Control Organisation. Mounjaro, developed as a dual GIP and GLP-1 receptor agonist, tackles crucial issues in managing type 2 diabetes and obesity by offering the benefits of once-weekly subcutaneous injection, improved glycemic control, decreased appetite, slower gastric emptying, and considerable weight loss, with initial dosing options of 2.5 mg and 5 mg available to boost patient adherence and achieve better long-term results.
Who Are The Top Market Participants Influencing The Non-Insulin Therapies For Diabetes Market?
Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC
Read the full non-insulin therapies for diabetes market report here:
Which Region Is Projected To Dominate The Non-Insulin Therapies For Diabetes Market During The Forecast Period?
North America was the largest region in the non-insulin therapies for diabetes market in 2025. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Non-Insulin Therapies For Diabetes Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=16494&type=smp
Browse Through More Reports Similar to the Global Non-Insulin Therapies For Diabetes Market 2026, By The Business Research Company
Patient Transport Services Global Market Report
https://www.thebusinessresearchcompany.com/report/patient-transport-services-global-market-report
Healthcare Transportation Service Global Market Report
Alternate Transportation Global Market Report
https://www.thebusinessresearchcompany.com/report/alternate-transportation-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model